Last reviewed · How we verify
XEN901
At a glance
| Generic name | XEN901 |
|---|---|
| Sponsor | Xenon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XEN901 CI brief — competitive landscape report
- XEN901 updates RSS · CI watch RSS
- Xenon Pharmaceuticals Inc. portfolio CI